Siemens Healthineers is partnering with Massachusetts General Hospital to establish a Therapy Command Center focused on advancing theranostics, a field that combines diagnostic imaging and targeted radiopharmaceutical therapies. The new center will support clinical decision-making and data collection across MGH and its affiliates in Massachusetts, Maine, and New Hampshire.

The collaboration builds on a two-decade relationship between the Malvern, Pennsylvania-based company and the Boston hospital. The initiative aims to provide physicians with real-time access to imaging and laboratory data, integrated with broader population health data sets, to help determine individualized treatment paths for cancer patients.

Theranostics is used in the treatment of cancers such as prostate, thyroid, and neuroendocrine tumors. Molecular imaging plays a key role in identifying disease extent and monitoring therapy response.
“The Therapy Command Center helps provide a framework that will enable the integration of a wide variety of patient imaging and laboratory data, combined with population-based data for enhanced individual patient outcomes,” said Dr. Umar Mahmood, chief of nuclear medicine and molecular imaging at Massachusetts General Hospital. “Our focus on examining radiation’s impact on tumors and normal tissues will further improve treatment protocols and outcomes while decreasing toxicity to normal organs.”

Researchers will use Siemens Healthineers’ Biograph Vision Quadra and Biograph Trinion PET/CT scanners to analyze how radiopharmaceuticals affect cancerous and healthy tissues at the molecular level. The data may help refine treatment protocols and reduce unintended side effects.

“This research collaboration … will enable innovations along the patient’s clinical pathway, provide precision diagnoses, and deliver highly effective forms of customized therapy,” said James Williams, Ph.D., head of Siemens Healthineers Molecular Imaging.

The center is expected to support both research and clinical operations, with a goal of scaling theranostic applications regionally.

U.S. Healthcare Homepage